Abstract
The activating receptor NKG2D, expressed by natural killer (NK) cells and CD8+ T cells, has a role in the specific killing of transformed cells. We examined NKG2D expression in patients with glioblastoma multiforme and found that NKG2D was downregulated on NK cells and CD8+ T cells. Expression of NKG2D on lymphocytes significantly increased following tumor resection and correlated with an increased ability to kill NKG2D ligand-positive tumor targets. Despite the presence of soluble NKG2D ligands in the sera of glioblastoma patients, NKG2D downregulation was primarily caused by tumor-derived tumor growth factor-β, suggesting that blocking of this cytokine may have therapeutic benefit.
Original language | English (US) |
---|---|
Pages (from-to) | 7-13 |
Number of pages | 7 |
Journal | Neuro-Oncology |
Volume | 12 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2010 |
Externally published | Yes |
Keywords
- GBM
- Immune escape NKG2D
- NK cell
- TGF-β
ASJC Scopus subject areas
- Oncology
- Clinical Neurology
- Cancer Research